ligand pharmaceuticals inc. Resources | BNET
On CNET: eMachines intros slim tower PC

BNET Industries

Ligand Pharmaceuticals Inc. (LGND) is in the Pharma Industry

Revenue
Dec 31 2007
$12.8M
Profit
Dec 31 2007
$281.6M
Market Cap
Oct 13 2008
$192.7M

Latest News and Analysis

Additional Resources

  • Ligand to Acquire Pharmacopeia for Stock and Contingent Value Rights

    Acquisition Would Result in Well Capitalized Company with Robust Royalty Assets and Broad Research Pipeline Conference Call Today at 5:30 p.m. Eastern SAN DIEGO -- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that it has entered into a definitive merger agreement to acquire Pharmacopeia (NASDAQ: PCOP),...

    Articles 2008-09-24

  • Beacon Equity Issues Technical Trade Alerts on Market Movers: GSAE, THMD, AKSN, LGND, CRAY, DAL

    DALLAS, Sept. 17 /PRNewswire/ -- BeaconEquity.com announces the availability of Trade Alerts on stocks making news today. Investors can view all of the daily trading notes for free by visiting: http://www.beaconequity.com/m Today's Trade Alerts include: Green Star Alternative Energy Inc. (Pink Sheets: GSAE), Thermadyne Holdings...

    Articles 2008-09-17

  • page 1 of 1

View Related Content by Tag Close

  • Incorporated: 1987
  • CEO: Mr. John L. Higgins
  • Employees: 59

Ligand Pharmaceuticals discovers and develops new drugs that address medical needs in the areas of thrombocytopenia, cancer, hepatitis C, hormone-related diseases, osteoporosis and inflammatory diseases. As of Dec 31 2007, Co. is a party of a number of arrangements that are in the development phase, including collaborations with: GlaxoSmithKline on eltrombopag for the treatment of bleeding in patients with idiopathic thrombocytopenia purpura; Wyeth on bazedoxifene for the prevention of postmenopausal osteoporosis; Pfizer on lasofoxifene for the prevention of osteoporosis in postmenopausal women; and TAP Pharmaceutical Products, Inc. on LGD-2941, a selective androgen receptor modulator.

Key Competitors

advertisement
Ligand Pharmaceuticals Inc. Company Info

Board of Directors

Dr. John W. Kozarich Ph.D.

Chairman

Mr. John L. Higgins

Mr. Jason M. Aryeh

Mr. Todd C. Davis

Ms. Elizabeth M. Greetham

Mr. David M. Knott

Mr. Jeffrey R. Perry

Contact Information

10275 Science Center Drive

San Diego, CA

http://www.ligand.com

858 550-7500

NAICS Code

Pharmaceutical Preparation Manufacturing: 325412
advertisement